Welcome to our dedicated page for Braxia Scientifi news (Ticker: BRAXF), a resource for investors and traders seeking the latest updates and insights on Braxia Scientifi stock.
IMPORTANT NOTICE: As of February 2025, Braxia Scientific Corp has ceased operations and is winding down the company. The company sold its operating assets in November 2024 and expects imminent delisting from the Canadian Securities Exchange. Historical news and developments are presented below for informational purposes.
News coverage of Braxia Scientific documented the company's journey from its establishment as a mental health treatment provider through its eventual operational wind-down. During its active period, the company generated news through clinic expansions, research developments, and regulatory approvals in the emerging field of psychedelic-assisted therapies for mental health conditions.
Major news events included the company's achievement in July 2021 of becoming the first organization to receive Health Canada approval for a multi-dose psilocybin-assisted therapy clinical trial. The company also announced its acquisition of KetaMD, a telemedicine platform, in August 2022 for approximately $6 million, marking its entry into the U.S. digital health market. Throughout its operational period, Braxia announced clinic openings across Canadian cities and reported on treatment volume growth and clinical research progress.
In 2024, news coverage shifted to document the company's financial difficulties and regulatory challenges. Significant developments included the August 2024 cease trade order from the Ontario Securities Commission, trading suspension on the Canadian Securities Exchange, leadership departures including the resignation of CEO Roger McIntyre, and the November 2024 sale of the company's Canadian Rapid Treatment Center assets. As of February 2025, the company announced it would wind down operations with no plans to continue business activities.
Investors and observers should note that Braxia Scientific trades on the OTC Pink marketplace with limited regulatory oversight and disclosure requirements. The company has stated it is unlikely any meaningful amount will be realized from remaining assets to satisfy liabilities or provide shareholder distributions. Any news developments regarding the company should be evaluated in the context of its defunct operational status.
Braxia Scientific Corp. has established direct billing with Medavie Blue Cross for ketamine treatments, offering 100% coverage for qualifying Canadian military veterans. This initiative aims to alleviate the financial burden of treatments at the Canadian Rapid Treatment Centre of Excellence. It is estimated that around 16% of full-time Canadian Armed Forces personnel experience depression, highlighting the significance of this coverage.
CEO Dr. Roger McIntyre emphasized the importance of this development, noting a rise in clinic bookings and the positive impact of ketamine treatments on veterans suffering from mental health disorders.
Braxia Scientific Corp. (CSE: BRAX, OTC: BRAXF) is participating in the AIMday on "Experimental Medicine in Psychiatry" hosted by Oxford University on July 7, 2021. CEO Dr. Roger McIntyre will discuss advancing psychiatric treatment discovery using ketamine and psychedelics. The event aims to enhance collaboration and data validation in drug development. Notable companies involved include Lundbeck, Compass Pathways, and Jazz Pharmaceuticals. Braxia focuses on innovative ketamine treatments for mental disorders through its multidisciplinary clinics in Canada.
Braxia Scientific Corp. (CSE: BRAX, OTC: BRAXF) announced its participation at the PSYCH Investor Summit on July 7, 2021. CEO Dr. Roger McIntyre will present on funding from the Canadian Institutes of Health Research for a groundbreaking Ketamine clinical trial targeting Bipolar Depression. The presentation aims to highlight Braxia's innovative therapeutics and the company's expanding network of clinics. The event will include a panel discussion featuring prominent industry leaders, focusing on future research and development trends.
Braxia Scientific Corp. has announced a fully funded clinical trial for bipolar depression, the largest of its kind exploring IV Ketamine. Supported by the Canadian Institute of Health Research, the trial will involve 100 participants across two sites in Toronto. With the existing limited treatment options for bipolar depression, this study aims to investigate the safety and efficacy of repeated IV Ketamine doses, highlighting the unmet need in mental health care. The findings are expected to bolster Braxia's position in innovative treatment development.
Braxia Scientific Corp. announced a major advancement in mental health research with funding from the Canadian Institute of Health Research for a large-scale clinical trial of intravenous (IV) Ketamine aimed at treating Bipolar Depression. This study, the largest of its kind, involves 100 participants and aims to evaluate the safety and efficacy of Ketamine, addressing a significant treatment gap as current options are limited. Dr. Josh Rosenblat will lead the trial across Toronto sites, further cementing Braxia’s leadership in innovative treatments for mental disorders.
Braxia Scientific Corp. (CSE: BRAX, OTC: BRAXF) announces its participation in the Psychedelics in Psychiatry and Beyond Virtual Conference on June 17, 2021. CEO Dr. Roger McIntyre will present a panel discussion titled "Patient Experience And Commercial Considerations When Launching Psychoactive Agents In Psychiatry". Additionally, Dr. McIntyre will hold virtual one-on-one meetings with institutional investors registered for the event. Braxia focuses on innovative ketamine treatments for depression and operates clinics in major Canadian cities.
Braxia Scientific Corp. (BRAXF) will participate in the Psychedelics in Psychiatry and Beyond Virtual Conference on June 17, 2021, hosted by H.C. Wainwright & Co. CEO Dr. Roger McIntyre will present a panel discussion titled "Patient Experience And Commercial Considerations When Launching Psychoactive Agents In Psychiatry". He will also hold virtual one-on-one meetings with registered institutional investors. Braxia focuses on innovative ketamine treatments for mental health disorders and operates clinics in cities including Mississauga, Toronto, Ottawa, and Montreal.
Braxia Scientific has established itself as a leader in the field of rapid-acting treatments for treatment-resistant depression (TRD) with the publication of the International Expert Opinion and Implementation Guidance in the American Journal of Psychiatry. Developed by CEO Dr. Roger S. McIntyre and a team of 26 experts, the guidelines set clinical parameters for the use of ketamine and esketamine. These drugs have gained attention since the FDA granted breakthrough status to esketamine in 2019, aimed at improving patient outcomes in TRD.
Braxia Scientific Corp. announced the appointment of Dr. David Greenberg to its Board of Directors. With over 30 years of experience, Dr. Greenberg is recognized in the field of Mental Health and Concussions, and has contributed to various education programs internationally. His role will enhance Braxia's focus on establishing standards of care for depression treatment and developing innovative ketamine therapies. The company also granted stock options for 9,750,000 shares at $0.395 each and engaged Stock Day Media for media services for $12,000 over three months.
Braxia Scientific Corp. (CSE: BRAX, OTC: BRAXF) announced that its common shares will commence trading under the new symbol 'BRAXF' on the OTC Market effective May 21, 2021. Previously, shares were traded under 'SHRMF'. The company focuses on developing ketamine treatments for depression and related disorders through its network of clinics. Braxia aims to lead in the standard of care for ketamine therapy and is committed to advancing research in psychedelic derivatives.
FAQ
What is the current stock price of Braxia Scientifi (BRAXF)?
What is the market cap of Braxia Scientifi (BRAXF)?
